Eledon Pharmaceuticals
ELDN
44 hedge funds and large institutions have $91.2M invested in Eledon Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 5 closing their positions.
360% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 5
63% more funds holding
Funds holding: 27 → 44 (+17)
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
19% more capital invested
Capital invested by funds: $76.8M → $91.2M (+$14.4M)
4.76% more ownership
Funds ownership: 22.89% → 27.66% (+4.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
+$5.32M |
| 2 |
PA
Perceptive Advisors
New York
|
+$4.48M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.38M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.32M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$2.92M |
| 2 |
Jennison Associates
New York
|
-$2.38M |
| 3 |
Morgan Stanley
New York
|
-$2.28M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.12M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.02M |
ELDN Hedge Fund Activity: Q4 2014 in Review
44 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q4 2014, worth a combined $91.2M — up 19% from $76.8M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ELDN positions and 5 closed out — a net gain of 18 holders — while 8 added to existing stakes and 6 trimmed.
The largest buyer was Kingdon Capital Management, adding an estimated $5.32M. The largest seller was Redmile Group, cutting an estimated $2.92M.
- 44 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q4 2014, up from 27 in Q3 2014.
- Funds reported $91.2M of Eledon Pharmaceuticals stock for Q4 2014, up 19% quarter-over-quarter.
- 23 funds opened new Eledon Pharmaceuticals positions in Q4 2014 and 5 closed out, a net change of +18 holders.
- The largest Eledon Pharmaceuticals buyer in Q4 2014 was Kingdon Capital Management, an estimated $5.32M added.
- The largest Eledon Pharmaceuticals seller in Q4 2014 was Redmile Group, an estimated $2.92M sold.
Based on aggregated 13F filings for Q4 2014.